Quantcast

Latest B-cell chronic lymphocytic leukemia Stories

2014-05-31 08:21:30

SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA®( )(ibrutinib) will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The results from this study will be presented at the 50(th) Annual Meeting of the American Society of...

2014-05-31 08:21:22

Results from Phase III RESONATE(TM) Trial Published in an Online First Edition of the New England Journal of Medicine SUNNYVALE, Calif., May 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced trial results of the first Phase III study (RESONATE, PCYC-1112-CA), a head-to-head comparison of IMBRUVICA® (ibrutinib) versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Patients receiving IMBRUVICA...

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of...

2014-05-31 08:20:57

Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine RARITAN, N.J., May 31, 2014 /PRNewswire/ -- Data from the international, multi-center Phase 3 PCYC-1112 (RESONATE(TM)) trial in 391 patients suggest single-agent ibrutinib (IMBRUVICA(®)) administered once-daily significantly lengthened progression-free survival (PFS) (median...

2014-05-31 08:20:48

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/ -- Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA(®)) suggest continued durable responses in patients with treatment-naive (TN) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data...

2014-05-30 10:16:03

Ohio State University Wexner Medical Center A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia (CLL). The study was published in the New England Journal of Medicine and led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). It identifies gene mutations that...

2014-05-29 15:51:33

University of Chicago Medical Center Pinpointing cause of relapse could lead to better therapies A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of...

2014-05-28 23:16:46

TG02 also shown to be equally active in CLL cells from patients prior to and following twelve months of ibrutinib therapy. San Diego (PRWEB) May 28, 2014 Tragara Pharmaceuticals, Inc. today announced the preliminary results of new preclinical research showing the activity of TG02, the company's unique oral cyclin dependent kinase (CDK) inhibitor, in chronic lymphocytic leukemia (CLL). Researchers at The Ohio State University demonstrated that TG02 is highly active in CLL cells derived...

2014-05-14 23:05:42

RnRMarketResearch.com adds “EpiCast Report Amyotrophic Lateral Sclerosis & Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2023” to its store. Develop business strategies by understanding the trends shaping and driving the global ALS & CLL market. Dallas, Texas (PRWEB) May 14, 2014 EpiCast Report: Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2023 Amyotrophic lateral sclerosis (ALS), often referred to as “Lou Gehrig’s Disease,” is a rare, but...

2014-05-14 16:29:31

- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin and JNJ-42756493 RARITAN, N.J., May 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related